A number of firms have modified their ratings and price targets on shares of RxSight (NASDAQ: RXST) recently: 4/20/2022 – RxSight was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “RxSight Inc. is a commercial-stage medical technology company focuses on patients following cataract surgery. The […]
RxSight (NASDAQ:RXST – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “RxSight Inc. is a commercial-stage medical technology company focuses on patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of […]
Zacks Investment Research lowered shares of RxSight (NASDAQ:RXST – Get Rating) from a hold rating to a sell rating in a research note published on Tuesday, Zacks.com reports. According to Zacks, “RxSight Inc. is a commercial-stage medical technology company focuses on patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight […]
RxSight Inc (NASDAQ:RXST – Get Rating) has received a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that […]
RxSight Inc (NASDAQ:RXST – Get Rating) – Investment analysts at SVB Leerink issued their Q1 2023 earnings estimates for RxSight in a report issued on Tuesday, March 8th. SVB Leerink analyst D. Antalffy expects that the company will post earnings of ($0.46) per share for the quarter. SVB Leerink currently has a “Buy” rating and […]